Comparative Pharmacology
Head-to-head clinical analysis: ESOMEPRAZOLE STRONTIUM versus PRILOSEC OTC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESOMEPRAZOLE STRONTIUM versus PRILOSEC OTC.
ESOMEPRAZOLE STRONTIUM vs PRILOSEC OTC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that inhibits the H+/K+ ATPase in gastric parietal cells, suppressing gastric acid secretion.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, suppressing gastric acid secretion.
40 mg orally once daily; for healing of erosive esophagitis, 40 mg orally once daily for 4-8 weeks; for maintenance of healing of erosive esophagitis, 20 mg orally once daily; for GERD, 20 mg orally once daily; for Helicobacter pylori eradication, 40 mg orally twice daily for 10 days in combination with antibiotics.
20 mg orally once daily for 14 days for frequent heartburn; may repeat 14-day course every 4 months.
None Documented
None Documented
Terminal elimination half-life: 1.0–1.5 hours in healthy subjects; prolonged in poor CYP2C19 metabolizers (up to 3.5 hours).
Approximately 0.5–1 hour in healthy subjects; longer (up to 3 hours) in slow metabolizers or hepatic impairment. Clinically, the duration of acid suppression exceeds the half-life due to accumulation in parietal cell canaliculi.
Primarily hepatic metabolism via CYP2C19 and CYP3A4. Approximately 80% of metabolites are excreted in urine and 20% in feces via bile. Less than 1% excreted unchanged.
Primarily hepatic metabolism; about 80% of metabolites are excreted in urine, and the remainder in feces via bile. Less than 1% of unchanged drug is excreted in urine.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor